Embrace the dividend release of drug trial reform, and Geely Dejie Fukang is listed in China

October 22, 2018 / AP / -- on October 20, gild Science Co., Ltd (NASDAQ Code: gild) held a press conference on the listing of JieFuKang ® in China in Beijing At the meeting, it was announced that the new anti AI drug JieFuKang (aikaoen propionate, E / C / F / TAF) approved on July 31 this year was officially launched The new drug for HIV-1 infection is the first approved single tablet regimen (STR) based on FTC / TAF for HIV treatment in China Do we need a fourth "90"? In order to achieve the goal of ending the AIDS epidemic by 2030, in 2014, UNAIDS set a "90-90-90" goal - 90% of HIV infected people were diagnosed, 90% of confirmed infected people received antiretroviral treatment (Art), 90% of infected people received antiretroviral treatment were suppressed [1] "Do we need to set higher goals, a fourth 90? Do HIV patients need better quality of life in addition to survival and live with dignity? " At the press conference on the listing of JieFuKang ® in China, Wang Fusheng, academician of the Chinese Academy of Sciences and the No 302 Hospital of the Chinese people's Liberation Army, asked a thought-provoking question According to the data of China Center for Disease Control and Prevention (hereinafter referred to as "CDC"), by the end of 2017, there were about 140000 newly diagnosed HIV infected people in China [2] In recent years, due to the expansion of screening scope, the number of confirmed cases has increased significantly At the same time, the number of HIV infected people receiving antiretroviral treatment has steadily increased Since 2003, the Chinese government has implemented the policy of "four exemptions and one care" to provide free antiretroviral treatment for all HIV infected people Although China's overall AIDS epidemic is still in a low state, it is still a major threat and challenge in the field of public health In some groups, the risk of infection is relatively high In 2017, the sentinel surveillance infection rate of men's same-sex behavior was 7.3% [3], with the main reported cases in eastern and central provinces and large and medium-sized cities, highlighting the plight of AIDS prevention and control for this special group It is also worrisome that the 20-29 age group has the highest number of new HIV cases per year In the past decade, China has invested a lot of resources in AIDS prevention and control With the increasing coverage of antiviral treatment, the mortality of AIDS has been reduced from 18.4% in 2005 to 4.6% in 2015 By 2017, about 758000 HIV / AIDS patients have survived in China [2] Effective treatment drug innovation, so that HIV from a fatal disease into a long-term management of chronic diseases With the prolongation of life span, long-term health and quality of life become important factors for patients to consider when choosing treatment Innovative backbone drugs, both safe and powerful, have a global perspective HIV antiviral treatment has entered the era of FTC / TAF (enteltabine / propofol tenofovir) as the backbone, integrating enzyme monolithic agents In the latest 2018 version of DHHS guidelines in the United States, the five options recommended for initial treatment include the combination of backbone drug FTC / TAF and integrase Benefiting from the new policy of optimizing the examination and approval of new drugs by the state, the integrated enzyme single-chip treatment scheme (E / C / F / TAF) based on FTC / TAF was approved by the State Food and drug administration The time interval between Chinese patients and foreign patients is becoming shorter and shorter JieFuKang ® is the first approved single tablet regimen (STR) based on FTC / TAF for HIV treatment in China This means that unlike in the past, it is possible to take multiple drugs every day Compared with multi tablet regimen, single tablet can provide better compliance and help patients adhere to treatment In the era of HIV chronicity, the long-term survival of patients needs more and more effective and safe programs "Diflucan ® is used in the initial treatment of patients, and can inhibit the virus quickly, effectively and permanently." Li Taisheng, director of infection department of Peking Union Medical College Hospital, said, "clinical trials have shown that in 144 weeks of treatment, JieFuKang ® has a long-lasting viral inhibition [4] [5] [6] In addition, the drug withdrawal rate of renal and skeletal adverse events was zero [7] [8] " To promote HIV disease management as the pioneer of biomedicine, Gilead has been at the forefront of HIV / AIDS prevention, treatment and cure for more than 30 years with the mission of "innovative therapy, curing persistent diseases" "Gilead fully supports China's efforts to deal with the HIV epidemic, and we are also very happy to bring a new treatment program, JieFuKang ®, to HIV patients in China." Luo Yongqing, global vice president and general manager of Geely, said, "gefk ® is one of our many kinds of FTC / TAF based therapies, and more products will enter China in the future We believe that the efficacy and safety of Diflucan ® can help meet the long-term health needs of Chinese HIV patients " Reference: [1] http:// [2] National AIDS and STD epidemic in December 2017, China Journal of AIDS and STD, 2018; 24 (02): 5 [3] 2017 national CDC annual report [4] Wohl D, et al J acquire immune defic synr 2016; 72 (1): 58-64 [5] Sax P, et al Lancet 2015; 385:2606 – 15 [6] arribas J, et al CROI 2017 Seattle, WA Poster #453 [7]Wohl D, et al JAIDS 2016;72:58-64, supplemental materials [8]Arribas JR, et al Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, And experimental abine (E / C / F) for initial HIV-1 treatment: Week 144 results J acquire immune defic syndr 2017; 75 (2): 211-218 about Gilead science Gilead science is a global leading biopharmaceutical company based on research and development, committed to the discovery, research and development, and commercialization of innovative therapies in the field of insufficient medical needs The mission of the company is to transform and simplify the treatment of patients with serious diseases around the world Gilead operates in more than 35 countries around the world and is headquartered in foster, California.